Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Deals

Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines

Fineline Cube Nov 16, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...

Company Deals

Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China

Fineline Cube Nov 16, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...

Company

Sirnaomics Announces Key Executive Promotions Effective November 15

Fineline Cube Nov 16, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite,...

Company Drug

Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study

Fineline Cube Nov 16, 2022

China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...

Company Drug

Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631

Fineline Cube Nov 16, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...

Company Drug

Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies

Fineline Cube Nov 16, 2022

Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...

Company Drug

CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation

Fineline Cube Nov 16, 2022

The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy

Fineline Cube Nov 16, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...

Company Drug

Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...

Company Deals

Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis

Fineline Cube Nov 16, 2022

Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...

Company Deals

Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round

Fineline Cube Nov 16, 2022

China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...

Company Drug

Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa

Fineline Cube Nov 15, 2022

Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...

Company Deals

Silk Round Fund and INA Invest in Indonesian Pharma Companies

Fineline Cube Nov 15, 2022

The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...

Company Drug

LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study

Fineline Cube Nov 15, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...

Company Drug

Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China

Fineline Cube Nov 15, 2022

China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...

Company

CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs

Fineline Cube Nov 15, 2022

CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...

Company Medical Device

Hotgen Receives NMPA Approval for HBV RNA Assay Kit

Fineline Cube Nov 15, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity

Fineline Cube Nov 15, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...

Company Drug

Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216

Fineline Cube Nov 15, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...

Company Drug

Yabao Receives FDA Clearance for Generic Nexavar

Fineline Cube Nov 15, 2022

China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...

Posts pagination

1 … 645 646 647 … 711

Recent updates

  • Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321
  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.